Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review
- PMID: 18373500
- DOI: 10.1111/j.1537-2995.2008.01693.x
Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review
Abstract
Background: Hyperhemolysis syndrome (HS) has been well described both in sickle cell disease (SCD) and non-SCD patients. The pathogenesis remains unclear. The possible mechanisms include bystander hemolysis, suppression of erythropoiesis, and destruction of red cells (RBCs) due to contact lysis via activated macrophages.
Case report: This study reports a child with SCD who presented with recurrent episode of HS. In the first episode, the hemoglobin (Hb) level decreased to 4.1 g per dL. He was treated with intravenous immunoglobulin (IVIG) and oral steroids, and transfusion was avoided. Six months later he had another episode of HS. The nadir Hb level decreased to 3.2 g per dL, and further transfusions were given with IVIG-IV methylprednisolone cover.
Results: RBC alloantibodies were not identified in pre- and posttransfusion samples in patient's serum in both episodes. HLA antibodies were also not detected.
Conclusion: This is the second reported case of recurrent HS in a child. Recent studies have shown that the adhesion molecules expressed on RBC erythroid precursor cells and reticulocytes can interact with macrophages and can cause hemolysis. Because RBC alloantibodies and HLA antibodies were not identified in this case, it is believed that the patient's cells and transfused cells were destroyed by macrophages either by direct contact lysis or by erythrophagocytosis. The possible mechanism of IVIG and steroids on suppression of macrophages resulting in cessation of hemolysis is discussed. Our case illustrates the danger of recurrent HS and the difficulty of balancing this against the need for transfusions in patients presented with severe hemolysis.
Similar articles
-
Treatment with intravenous immunoglobulin and steroids may correct severe anemia in hyperhemolytic transfusion reactions: case report and literature review.Transfus Med Rev. 2010 Jan;24(1):64-7. doi: 10.1016/j.tmrv.2009.09.006. Transfus Med Rev. 2010. PMID: 19962576 Review.
-
Successful treatment of recurrent hyperhemolysis syndrome with immunosuppression and plasma-to-red blood cell exchange transfusion.Transfusion. 2014 Feb;54(2):384-8. doi: 10.1111/trf.12258. Epub 2013 May 21. Transfusion. 2014. PMID: 23692505
-
Hyperhemolysis syndrome in patients with sickle cell anemia: report of three cases.Transfusion. 2015 Jun;55(6 Pt 2):1394-8. doi: 10.1111/trf.12993. Epub 2015 Feb 10. Transfusion. 2015. PMID: 25677578
-
Hyperhemolysis during the evolution of uncomplicated acute painful episodes in patients with sickle cell anemia.Transfusion. 2006 Jan;46(1):105-10. doi: 10.1111/j.1537-2995.2006.00679.x. Transfusion. 2006. PMID: 16398738
-
Anti-N and anti-Doa immunoglobulin G alloantibody-mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC-201: case report and review of the literature.Transfusion. 2019 Jun;59(6):1907-1910. doi: 10.1111/trf.15198. Epub 2019 Feb 15. Transfusion. 2019. PMID: 30768787 Review.
Cited by
-
Alloimmunization in patients with sickle cell disease and underrecognition of accompanying delayed hemolytic transfusion reactions.Transfusion. 2019 Jul;59(7):2282-2291. doi: 10.1111/trf.15328. Epub 2019 Apr 25. Transfusion. 2019. PMID: 31021439 Free PMC article.
-
Stem cell-derived erythrocytes as upcoming players in blood transfusion.ISBT Sci Ser. 2013 Jun;8(1):165-171. doi: 10.1111/voxs.12048. ISBT Sci Ser. 2013. PMID: 26229549 Free PMC article.
-
Adverse events of red blood cell transfusions in patients with sickle cell disease.Transfus Apher Sci. 2022 Oct;61(5):103557. doi: 10.1016/j.transci.2022.103557. Epub 2022 Aug 29. Transfus Apher Sci. 2022. PMID: 36064527 Free PMC article. Review.
-
Antigen density dictates RBC clearance, but not antigen modulation, following incompatible RBC transfusion in mice.Blood Adv. 2021 Jan 26;5(2):527-538. doi: 10.1182/bloodadvances.2020002695. Blood Adv. 2021. PMID: 33496748 Free PMC article.
-
Alloimmunization and hyperhemolysis in sickle cell disease.Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):653-659. doi: 10.1182/hematology.2023000499. Hematology Am Soc Hematol Educ Program. 2023. PMID: 38066873 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials